Rxivist logo

Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes

By Aidan McGlinchey, Tim Sinioja, Santosh Lamichhane, Partho Sen, Johanna Bodin, Heli Siljander, Alex M. Dickens, Dawei Geng, Cecilia Carlsson, Daniel Duberg, Jorma Ilonen, Suvi Virtanen, Hubert Dirven, Hanne Friis Berntsen, Karin Zimmer, Unni C. Nygaard, Matej Oresic, Mikael Knip, Tuulia Hyotylainen

Posted 25 Mar 2019
bioRxiv DOI: 10.1101/588350 (published DOI: 10.1016/j.envint.2020.105935)

In the last decade, increasing incidence of type 1 diabetes (T1D) stabilized in Finland, a phenomenon that coincides with tighter regulation of perfluoroalkyl substances (PFAS). Here, we quantified PFAS to examine their effects, during pregnancy, on lipid and immune-related markers of T1D risk in children. In a mother-infant cohort (264 dyads), high PFAS exposure during pregnancy associated with decreased cord serum phospholipids and progression to T1D-associated islet autoantibodies in the offspring. This PFAS-lipid association appears exacerbated by increased human leukocyte antigen-conferred risk of T1D in infants. Exposure to a single PFAS compound or a mixture of organic pollutants in non-obese diabetic mice resulted in a lipid profile characterized by a similar decrease in phospholipids, a marked increase of lithocholic acid, and accelerated insulitis. Our findings suggest that PFAS exposure during pregnancy contributes to risk and pathogenesis of T1D in offspring.

Download data

  • Downloaded 947 times
  • Download rankings, all-time:
    • Site-wide: 28,734
    • In molecular biology: 768
  • Year to date:
    • Site-wide: 94,681
  • Since beginning of last month:
    • Site-wide: 131,498

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide